Daotai L Nie from 7400 Wentworth Dr, Springfield, IL 62711, age 58, Phone: 3136479616

Fc101 As A Method Of Treatment For Cancer
view source
US Patent:

6660765, Dec 9, 2003
Filed:

Aug 2, 2002
Appl. No.:

10/211466
Inventors:

Roy E. Wuthier - Columbia SC
Daotai Nie - Grosse Pointe Farms MI
Assignee:

University of South Carolina - Columbia SC
International Classification:

A61K 31335
US Classification:

514450
Abstract:

The present invention provides a treatment for angiogenic diseases, including solid tumors. The treatment consists of administering therapeutically active dosages of FC101, resulting in a reduction in endothelial cell proliferation and inhibition of new blood vessel formation. FC101 can also be used as a lead compound to develop other pharmacologically-active compounds, by adding or substituting different functional groups for those already present on the FC101 molecule.

Fc101 And Analogs As A Method Of Treatment For Cancer
view source
US Patent:

7078433, Jul 18, 2006
Filed:

Oct 29, 2003
Appl. No.:

10/696760
Inventors:

Roy E. Wuthier - Columbia SC, US
Daotai Nie - Grosse Pointe Farms MI, US
Assignee:

University of South Carolina - Columbia SC
International Classification:

A01N 43/16
A61K 31/35
US Classification:

514460
Abstract:

The present invention provides a treatment for angiogenic diseases, including solid tumors. The treatment consists of administering therapeutically active dosages of FC101, resulting in a reduction in endothelial cell proliferation and inhibition of new blood vessel formation. FC101 can also be used as a lead compound to develop other pharmacologically-active compounds, by adding or substituting different functional groups for those already present on the FC101 molecule.

Use Of An Angiogenesis Inhibitor As A Lead Compound In Drug Development
view source
US Patent:

20010011100, Aug 2, 2001
Filed:

Mar 29, 2001
Appl. No.:

09/821196
Inventors:

Roy Wuthier - Columbia SC, US
Daotai Nie - Detroit MI, US
International Classification:

A61K031/366
US Classification:

514/456000
Abstract:

The present invention provides a treatment for angiogenic diseases, including solid tumors. The treatment consists of administering therapeutically active dosages of FC101, resulting in a reduction in endothelial cell proliferation and inhibition of new blood vessel formation. FC101 can also be used as a lead compound to develop other pharmacologically-active compounds, by adding or substituting different functional groups for those already present on the FC101 molecule.

Angiogenesis Inhibitor For The Treatment Of Endothelial Cell Proliferation
view source
US Patent:

62253409, May 1, 2001
Filed:

Mar 30, 1999
Appl. No.:

9/281577
Inventors:

Roy E. Wuthier - Columbia SC
Daotai Nie - Detroit MI
Assignee:

University of South Carolina - Columbia SC
International Classification:

A61K 3135
US Classification:

514456
Abstract:

The present invention provides a treatment for angiogenic diseases, including solid tumors. The treatment consists of administering therapeutically active dosages of FC101, resulting in a reduction in endothelial cell proliferation and inhibition of new blood vessel formation. FC101 can also be used as a lead compound to develop other pharmacologically-active compounds, by adding or substituting different functional groups for those already present on the FC101 molecule.

Angiogenesis Inhibitor For The Treatment Of Cancer
view source
US Patent:

59326115, Aug 3, 1999
Filed:

Nov 21, 1997
Appl. No.:

8/975813
Inventors:

Roy E. Wuthier - Columbia SC
Daotai Nie - Detroit MI
Assignee:

University of South Carolina - Columbia SC
International Classification:

A61K 3135
US Classification:

514456
Abstract:

The present invention provides a treatment for angiogenic diseases, including solid tumors. The treatment consists of administering therapeutically active dosages of FC101, resulting in a reduction in endothelial cell proliferation and inhibition of new blood vessel formation. FC101 can also be used as a lead compound to develop other pharmacologically-active compounds, by adding or substituting different functional groups for those already present on the FC101 molecule.

Daotai L Nie